Lung disease often develops silently, and early signs are easily missed until symptoms become severe and harder to treat. Recognizing these respiratory symptoms sooner can significantly change patient outcomes. AstraZeneca Switzerland is committed to making lung health a priority by raising awareness of risk factors, encouraging early medical check-ups, and building clinical partnerships that strengthen respiratory care across the country.




Expert perspectives on lung health

Hear from a patient organisation and a healthcare professional about
lung health and ongoing support.


Prof. Dr. med. Daniel Franzen

Head of Internal Medicine and Co-Chief of Pneumology Spital Uster
 

Recognising lung disease and improving care

  • Why earlier diagnosis matters
  • The value of coordinated care and follow-up
  • Helping people manage their condition over time

Lung health is not a niche topic. It is about prevention, early detection and the chance to live longer and, above all, healthier.


Joel Kaiser

Technical Specialist, CPAP and Home Ventilation
Deputy Head of Home Therapy, Lungenliga beider Basel
 

Understanding symptoms and finding support

  • Why people may put off seeking help
  • How clear information can build understanding
  • Support available through the Lungenliga

Symptoms become part of everyday life before those affected even notice that something has changed.




Lung Cancer


Lung cancer remains one of the most severe cancer diagnoses in Switzerland, primarily because it is frequently detected in advanced stages. Early-stage lung cancer (TNM Stage I and Stage II; localised, potentially resectable) often presents no symptoms, limiting treatment options once symptoms appear. While smoking is the primary risk factor, a significant number of cases occur in non-smokers. This highlights the critical importance of early lung cancer detection, which substantially improves treatment success and survival rates.1-4


4,400-4,500

people in Switzerland are diagnosed with lung cancer every year, and about 3,200 die from the disease. It's the 2nd most common cancer in men and 3rd in women.1,2

80-90%

of lung cancer cases are linked to smoking. 15–20% of patients with lung cancer never smoked.3,4

~70

years is the average age at diagnosis for both men and women.2

Only 25-30%

of cases are detected at an early stage (TNM Stage I: 19.2%, Stage II: 7.2%), as symptoms usually appear only in later stages.1

20-28%

is the 5-year survival rate in Switzerland — around 20% for men, 28% for women. As symptoms may not become apparent until the disease has progressed, lung cancer is frequently diagnosed at an advanced stage.2




COPD


Chronic Obstructive Pulmonary Disease (COPD) is a widespread, progressive condition characterised by irreversible airway obstruction. COPD develops gradually over time, with smoking and air pollution being the most common causes.1,2


~400k

people in Switzerland live with COPD, a condition that cannot be cured but can be managed much more effectively when it is detected early.1,3

40-55

years of age is when COPD is usually detected, although the disease develops gradually and often remains unnoticed for a long time.4 COPD is the 3rd leading cause of premature death (4000 yearly in CH)5,6

90%

of people with COPD were long-term heavy smokers.1,2 Around 20% of people who smoke develop COPD.7,8

Up to 847

million CHF detected at an early stage in healthcare costs annually.3

10k

is the CHF more per year for COPD patients with poor medication adherence. Potentially avoidable hospitalizations (PAHs) represent an unnecessary burden and major hospital cost.9,10




Asthma


Asthma is a chronic inflammatory disease of the airways characterised by shortness of breath, wheezing, coughing, and chest tightness. When severe or poorly controlled, asthma can significantly impair a patient's quality of life.1


5.4%

of the Swiss population (15+) have asthma (6.1% of women, compared with 4.7% of men).2 Despite optimised treatments, the global prevalence of asthma continues to rise.1

5-10%

of asthma patients suffer from severe asthma and account for 50% of asthma-related financial burden.3

88

people in Switzerland died from asthma in 2024.4

45%

of severe asthma patients in Switzerland have either uncontrolled or partially controlled asthma.5

84%

of severe asthma patients are likely to have an eosinophilic phenotype.6




Our stories of progress in cancer care


For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch




References

Lung Cancer:​

  1. Galli F, Rohrmann S, Lorez M; NICER Working Group. Lung cancer survival in Switzerland by histology, TNM stage and age at diagnosis. Swiss Cancer Bulletin. 2019;39(1):69-73.​
  2. Bundesamt für Statistik. Schweizerischer Krebsbericht 2021. https://www.bfs.admin.ch/bfs/en/home/news/whats-new.assetdetail.19305696.html (Accessed 10.2026).​
  3. Krebsliga Schweiz. Was ist Lungenkrebs? https://www.krebsliga.ch/ueber-krebs/krebsarten/lungenkrebs-bronchialkarzinom/was-ist-lungenkrebs/ (Accessed 10.2026). ​
  4. Rosenfluh Verlag. Onkologie. https://www.rosenfluh.ch/media/onkologie/2025/04/Umweltfaktoren-Strahlung-Genetik-Update-Lungenkrebs-bei-Nichtrauchern.pdf (Accessed 10.2026).​

​

COPD:​

  1. Lungenliga Schweiz. COPD – Chronisch obstruktive Lungenkrankheit: Ursachen, Symptome und Behandlung. https://www.lungenliga.ch/krankheiten-therapien/copd (Accessed 10.2026).​
  2. Bridevaux PO, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland (SAPALDIA). Eur Respir J. 2010;36(6):1259–1269.​
  3. Medinfo-Verlag. Pilot integrierter Patientenpfad COPD. https://www.medinfo-verlag.ch/pilot-integrierter-patientenpfad-copd/ (Accessed 10.2026).​
  4. Lungenliga Schweiz. COPD – Früh erkennen – wirksam behandeln. https://lungenliga.rokka.io/dynamic/noop/60292cb841d085e1ec2a17124b4d0b72c71b3069/10031006d-copd.pdf (Accessed 10.2026).​
  5. WHO / Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2023. Seattle: Institute for Health Metrics and Evaluation (IHME); 2025. https://www.healthdata.org/research-analysis/library/global-burden-disease-2023-findings-gbd-2023-study (Accessed 10.2026).​
  6. Klinik Hirslanden. COPD – Frühzeitige Diagnose und Therapie verhindert Fortschreiten der Krankheit. Medienmitteilung; 2024. https://www.hirslanden.ch/de/klinik-hirslanden/news-und-medien/medienmitteilungen/copd-diagnose-und-therapie.html (Accessed 10.2026).​
  7. Terzikhan N, Verhamme KM, Hofman A, et al. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. Eur J Epidemiol. 2016;31(8):785–792.​
  8. Kamal R, Srivastava AK, Kesavachandran CN. Meta-analysis approach to study the prevalence of chronic obstructive pulmonary disease among current, former and non-smokers. Toxicol Rep. 2015;2:1064–1074.​
  9. Bukanova-Berend D, Campbell-James T, Vogel J. Hospitalizations and inpatient resource consumption of patients suffering from chronic disease - Past trend and forecast for Switzerland. BMC Health Serv Res. 2025;25(1):1514. Published 2025 Nov 24. doi:10.1186/s12913-025-13687-5.
  10. Gouveia A, et al. Potentially Avoidable Hospitalizations by Asthma and COPD in Switzerland from 1998 to 2018: A Cross-Sectional Study. Healthcare (Basel). 2023;11(9):1229.​

 

Asthma:​

  1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2026. Updated May 2026. Available from: https://www.ginasthma.org (Accessed 10.2026).​
  2. Schweizerisches Gesundheitsobservatorium (Obsan). Chronische Atemwegserkrankungen bei Personen ab 15 Jahren. Indikator des nationalen Monitorings nichtübertragbarer Krankheiten (MONAM). Neuchâtel: Obsan. https://ind.obsan.admin.ch/indicator/monam/atemwegserkrankungen-alter-15 (Accessed 10.2026).​
  3. Hekking PPW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.​
  4. Bundesamt für Statistik (BFS). Sterbefälle und Sterbeziffern wichtiger Todesursachen, nach Alter, Frauen/Männer. Neuchâtel: BFS; 2024. https://www.bfs.admin.ch/asset/de/je-d-14.03.04.01.02 (Accessed 10.2026).​
  5. Jaun F, et al. Characteristics of Severe Asthma Patients and Predictors of Asthma Control in the Swiss Severe Asthma Registry. Respiration. 2023;102(11):944–955.​
  6. Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830.​

Veeva ID: CH-14016
Date of preparation: November 2026